PCM
LGND icon

Pavaki Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Pavaki Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.51M Hold
11,100
– – 1.22% 17
2026
Q1 		$2.22M Hold
11,100
– – 0.94% 21
2025
Q4 		$2.1M Buy
+11,100
New +$2.13M 0.82% 27

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Pavaki Capital Management's LGND Position: Q2 2026 in Review

Pavaki Capital Management held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 11,100 shares worth $3.51M. The position accounts for 1.22% of the portfolio, ranked #17.

Pavaki Capital Management first reported a position in LGND in Q4 2025 and has held it in 3 quarters since. 392 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Pavaki Capital Management held 11,100 shares of Ligand Pharmaceuticals worth $3.51M as of Q2 2026.
  • Pavaki Capital Management left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
  • Ligand Pharmaceuticals made up 1.22% of Pavaki Capital Management's portfolio in Q2 2026, its #17 holding.
  • Pavaki Capital Management first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 392 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Pavaki Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.